News Posts List
New Y-trap Technology Shows Promise as Cancer Immunotherapy
04/06/2018
A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors.
Combinations: The Future of Renal Cell Carcinoma Treatment?
04/05/2018
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with an estimated 65,340 patients expected to be diagnosed in 2018 in the United States alone. Nearly a third of those patients will be diagnosed with the advanced or metastatic disease.
Nivolumab, ipilimumab combination improves advanced renal cell carcinoma survival
04/04/2018
Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.
When you have kidney cancer...
02/21/2018
There's one important thing to remember, when you've been diagnosed with kidney cancer. What is it?
Videos:2017 Kidney Cancer Association Patient & Survivor Conference
01/09/2018
Videos from KCA patient and survivor conference that held in North Carolina on December 9th, 2017 is now available online: Welcome and Introduction to the Kidney Cancer Association/ Genetics of RCC: Is my family at risk?/ Advances in the Surgical Treatment of RCC/ Adjuvant treatment of RCC/ Sequencing therapies for metastatic RCC/ Use of Immunotherapy in RCC/ Recent clinical trial advances in RCC/ Integrating early palliative care in RCC management/ Managing the side effects of RCC treatment/ Panel for Questions and Conclusions.
FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma
01/02/2018
"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."
FDA Approves Adjuvant Sunitinib for High-Risk RCC
12/31/2017
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.
U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
12/19/2017
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.
NICE recommends Eisai’s Kisplyx for renal cell carcinoma
12/14/2017
Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer
12/12/2017
The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...
News Feed